PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Clinical Trials
5.0k
Trial Phases
6 Phases
Drug Approvals
69
Drug Approvals
Rimegepant Sulfate Orally Disintegrating Tablets
- Product Name
- 乐泰可
- Approval Number
- 国药准字HJ20240004
- Approval Date
- Jan 23, 2024
Ritlecitinib Tosylate Capsules
- Product Name
- 乐复诺
- Approval Number
- 国药准字HJ20230118
- Approval Date
- Oct 18, 2023
- Prev
- 1
- 2
- Next
Clinical Trials
Distribution across different clinical trial phases (3920 trials with phase data)• Click on a phase to view related trials
A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
- Conditions
- Non-muscle Invasive Bladder Cancer
- Interventions
- First Posted Date
- 2025-10-03
- Last Posted Date
- 2025-10-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 294
- Registration Number
- NCT07206225
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸AdventHealth Orlando, Orlando, Florida, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
A Study to Learn if Multiple Doses of the Study Medicine Called Carbamazepine Changes How the Body Processes the Other Study Medicine PF-07248144
- First Posted Date
- 2025-09-30
- Last Posted Date
- 2025-09-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT07198035
- Locations
- 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Other, Belgium
A Study to Learn About the Medicine Called Ritlecitinib in Adults With Severe Alopecia Areata in Real-world Settings
- First Posted Date
- 2025-09-30
- Last Posted Date
- 2025-09-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 123
- Registration Number
- NCT07200128
- Locations
- 🇺🇸
Pfizer, New York, New York, United States
A Study to Learn If the Study Medicine Called PF-08049820 Changes How the Body Processes the Other Study Medicines Called Oral Contraceptives, Midazolam, and Dabigatran in Healthy Adult Female Participants
- Conditions
- Atopic Dermatitis
- Interventions
- Drug: Portia (EE and LN) or equivalent oral tablet
- First Posted Date
- 2025-09-24
- Last Posted Date
- 2025-09-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 16
- Registration Number
- NCT07190430
Describing Treatment Patterns and Creating an Updated Treatment Flow in an Ulcerative Colitis Population
- Conditions
- Ulcerative Colitis
- Interventions
- Drug: Non-Interventional Study
- First Posted Date
- 2025-09-16
- Last Posted Date
- 2025-09-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 4000
- Registration Number
- NCT07177209
- Locations
- 🇬🇧
Pfizer, Walton Oaks, United Kingdom
- Prev
- 1
- 2
- 3
- 4
- 5
- 640
- Next
News
Nurix Therapeutics Advances Bexobrutideg Toward Pivotal CLL Trials with Strong Phase 1 Data
Nurix Therapeutics announced plans to initiate pivotal trials for bexobrutideg in relapsed/refractory chronic lymphocytic leukemia patients in the second half of 2025, including both accelerated approval and confirmatory Phase 3 studies.
Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer to Advance Oncology Pipeline
Zymeworks Inc. has appointed Dr. Adam Schayowitz as Acting Chief Development Officer to advance the company's broad portfolio of nominated product candidates and strengthen strategic partnerships.
COVID-19 Boosters Reduce Hospitalizations and Deaths by Up to 64% in Large Veterans Study
A large study of nearly 300,000 U.S. military veterans found that 2024-2025 COVID-19 mRNA boosters reduced emergency department visits by 29%, hospitalizations by 39%, and deaths by 64% compared to unvaccinated individuals.
Nilo Therapeutics Emerges from Stealth with $101 Million to Develop Neural Circuit-Based Immunomodulation Therapies
Nilo Therapeutics launched with $101 million Series A financing led by The Column Group, DCVC Bio, and Lux Capital to develop a new class of medicines targeting neural circuits in immune diseases.
Former FDA Vaccine Chief Peter Marks Joins Eli Lilly to Lead Infectious Disease and Molecule Discovery
Peter Marks, former director of the FDA's Center for Biologics Evaluation and Research, has joined Eli Lilly as senior vice president of molecule discovery and head of infectious disease work.
Valneva Secures $500M Debt Facility to Support Lyme Disease Vaccine Development
Valneva secured a $500 million debt facility with Pharmakon Advisors, extending repayment from Q1 2026 to Q4 2030 with improved financial terms.
Halozyme Acquires Elektrofi for $750M to Expand Ultra-High Concentration Drug Delivery Technology
Halozyme Therapeutics has agreed to acquire Elektrofi for $750 million upfront plus up to $150 million in milestone payments, gaining access to breakthrough Hypercon microparticle technology.
Biopharma M&A Activity Surges in Q3 2025 with $55.7 Billion in Acquisitions
The biopharmaceutical sector experienced a significant surge in high-value acquisitions during Q3 2025, with four of the year's five largest deals occurring in the past four months.
TAHO Pharma Submits World's First Apixaban Oral Dissolving Film to FDA for Stroke Survivors with Swallowing Difficulties
TAHO Pharmaceuticals has submitted a New Drug Application to the FDA for TAH3311, the world's first apixaban oral dissolving film designed for patients with swallowing difficulties.
Moffitt Cancer Center Reports Promising Results for Avelumab-Radiation Combination in Leptomeningeal Disease
Researchers at Moffitt Cancer Center demonstrated that combining avelumab immunotherapy with whole brain radiotherapy showed promising safety and efficacy in treating leptomeningeal disease, a devastating cancer complication.